Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
275M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
14.6M
-
Shares change
-
-2.17M
-
Total reported value, excl. options
-
$54.4M
-
Value change
-
-$11.1M
-
Put/Call ratio
-
0
-
Number of buys
-
28
-
Number of sells
-
-44
-
Price
-
$3.72
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q2 2022
79 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value as of Q2 2022.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.6M shares
of 275M outstanding shares and own 5.32% of the company stock.
Largest 10 shareholders include FMR LLC (3.3M shares), Nantahala Capital Management, LLC (1.64M shares), VANGUARD GROUP INC (1.07M shares), BlackRock Inc. (1.05M shares), Artal Group S.A. (1.04M shares), FRANKLIN RESOURCES INC (811K shares), Sands Capital Ventures, LLC (725K shares), Alphabet Inc. (641K shares), RENAISSANCE TECHNOLOGIES LLC (524K shares), and TYBOURNE CAPITAL MANAGEMENT (HK) LTD (500K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.